<DOC>
	<DOCNO>NCT02059564</DOCNO>
	<brief_summary>A Phase 1b , Exploratory , Randomized , Partially Single Blinded , Placebo Open Label Controlled , Parallel Group Study Assess Effects HM11260C Active Comparator Gastric Emptying Beta-Cell Response Subjects Type 2 Diabetes Mellitus</brief_summary>
	<brief_title>A Phase 1b Study LAPS-Exendin Subjects Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Primary Objective - effect multiple different weekly monthly dos HM11260C liraglutide ( Victoza ) active control gastric empty Secondary Objectives - evaluate pharmacodynamic ( PD ) effect multiple weekly monthly dos HM11260C liraglutide Mixed Meal Tolerance Test - evaluate islet β-cell function grade glucose infusion ( GGI ) different dos HM11260C liraglutide - evaluate safety tolerability different dos HM11260C liraglutide - evaluate pharmacokinetic ( PK ) effect multiple weekly monthly dos HM11260C</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Adults ≥18 ≤ 70 year age time Screening Visit History type 2 diabetes Body mass index ( BMI ) ≥18 ≤45 kg/m2 Screening Visit Use approve method contraception Ability provide write informed consent Type 1 diabetes Significant acute diabetic proliferative retinopathy severe neuropathy Systolic blood pressure &gt; 160 mm Hg and/or diastolic blood pressure &gt; 100 mm Hg screening Pregnant lactate woman Participation investigational study within 30 day prior randomization History major surgery within 6 month prior Screening History serious adverse reaction hypersensitivity product component . History renal disease significantly abnormal kidney function test Screening History hepatic disease significantly abnormal liver function test History active infection within 30 day prior Randomization Presence clinically significant physical , laboratory , ECG finding Screening , opinion Investigator , may interfere aspect study conduct interpretation result Concurrent condition could interfere safety and/or tolerability measurement per investigator Donation loss &gt; 500 mL blood blood product within 56 day Randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Exendin-4</keyword>
</DOC>